产品
编 号：F203643
分子式：C19H14ClN3O4
分子量：383.79
分子式：C19H14ClN3O4
分子量：383.79
产品类型
规格
价格
是否有货
结构图
CAS No: 170142-20-8
产品详情
生物活性：
ZD-9379 is a potent, orally active, and brain penetrant full antagonist at the glycine site of the NMDA receptor. ZD-9379 has neuroprotective effect.
体内研究：
ZD-9379 (5 mg/kg) reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion.Animal Model:Male Sprague-Dawley rats weighing 290 to 340 g undergoing permanent middle cerebral artery occlusion (MCAO)
Dosage:5 mg/kg
Administration:Group1: a 5-mg/kg bolus of ZD-9379 over 5 minutes followed by 5 mg/kg per hour drug infusion for 4 hours beginning 30 minutes before MCAO.Group 2: (post-MCAO treatment group), a 5-mg/kg bolus of ZD-9379 30 minutes after MCAO followed by 5 mg/kg per hour drug infusion for 4 hours.
Result:Initiated before or after MCAO significantly reduced the number of Spreading depressions (SDs) and infarct volume in a permanent focal ischemia model.
ZD-9379 is a potent, orally active, and brain penetrant full antagonist at the glycine site of the NMDA receptor. ZD-9379 has neuroprotective effect.
体内研究：
ZD-9379 (5 mg/kg) reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion.Animal Model:Male Sprague-Dawley rats weighing 290 to 340 g undergoing permanent middle cerebral artery occlusion (MCAO)
Dosage:5 mg/kg
Administration:Group1: a 5-mg/kg bolus of ZD-9379 over 5 minutes followed by 5 mg/kg per hour drug infusion for 4 hours beginning 30 minutes before MCAO.Group 2: (post-MCAO treatment group), a 5-mg/kg bolus of ZD-9379 30 minutes after MCAO followed by 5 mg/kg per hour drug infusion for 4 hours.
Result:Initiated before or after MCAO significantly reduced the number of Spreading depressions (SDs) and infarct volume in a permanent focal ischemia model.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备